US-based Neuro-Horizon Pharma licenses promising compounds from NTU Singapore to combat multidrug-resistant tuberculosis
Aug 2, 2022, 11:44 AM
Title :
US-based Neuro-Horizon Pharma licenses promising compounds from NTU Singapore to combat multidrug-resistant tuberculosis
URL of media release :
US-based Neuro-Horizon Pharma licenses promising compounds from NTU Singapore to combat multidrug-resistant tuberculosis